nelfinavir has been researched along with AIDS Seroconversion in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (18.18) | 18.2507 |
| 2000's | 18 (81.82) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asuncion, A; Berry, GJ; Chapman, CH; Dimmick, KW; Filion, EJ; Green, J; Hara, W; Loo, BW; Marko, D; Shen, J; Tran, PT; Wakelee, H | 1 |
| Berenguer, J; Casas, E; Castro, A; de Mendoza, C; López-Calvo, S; Núńez, M; Podzamczer, D; Rosón, B; Rubio, A; Soriano, V; Valer, L | 1 |
| Becker, M; Donahue, JP; Dowdy, D; Haas, DW; Hulgan, T; Nicotera, J; Price, J; Raffanti, S; Ratnam, KK; Unutmaz, D | 1 |
| Carr, A; Cooper, DA; Cunningham, PH; Duncombe, C; Grey, PA; Hecht, FM; Kahn, JO; Kaufmann, GR; Petersen, A; Quan, DC; Smith, DE; Zaunders, JJ | 1 |
| Barberá, MJ; Barceló, JJ; Ferrer, E; Gallart, T; García, A; García, F; Gatell, JM; Lacarcel, M; Maleno, MJ; Martínez, C; Miró, JM; Plana, M; Podzamczer, D | 1 |
| Briganti, E; Castelli, P; Cusato, M; Delle Foglie, P; Fabris, P; Gatti, F; Maserati, R; Mori, F; Nardini, G; Regazzi, M; Roda, R; Sacchelli, L; Testa, L; Villani, P; Zucchi, P | 1 |
| Bleiber, G; Buclin, T; Colombo, S; Décosterd, L; Furrer, H; Goldstein, D; Rotger, M; Soranzo, N; Sprenger, R; Telenti, A | 1 |
| Bates, DE; Herman, RJ | 1 |
| Hirsch, HH; Mossdorf, E | 1 |
| Coleman, CI; White, CM | 1 |
| Anastos, K; Cohen, M; Cole, S; Hessol, NA; Justman, J; Kaplan, RC; Lu, D; Shi, Q; Tien, PC; Vigen, C; Young, M | 1 |
| Efron, B; Lawrence, J; Merigan, TC; Montoya, J; Pesano, R; Schapiro, J; Winslow, D; Winters, M; Zolopa, A | 1 |
| Kessler, CM; Racoosin, JA | 1 |
| Chapman, S; Clendeninn, NJ; Powderly, WG; Quart, B; Saag, MS; Yu, G | 1 |
| Addo, M; Berthold, HK; Parhofer, KG; Ritter, MM; Rockstroh, JK; Schliefer, K; Spengler, U; Wasmuth, JC | 1 |
| Angel, JB; Badley, AD; Cameron, DW; Cassol, S; Chambers, KA; Gallicano, K; Hawley-Foss, N; Kravcik, S; Mandy, F; Parato, K; Phenix, BN | 1 |
| Alessi, F; Bonfanti, P; Carradori, S; Di Cintio, E; Faggion, I; Fortuna, P; Gabbuti, A; Ghiselli, G; Landonio, S; Martinelli, C; Parazzini, F; Pusterla, L; Quirino, T; Timillero, L; Valsecchi, L | 1 |
| Elmadfa, I; Pernerstorfer-Schoen, H; Rieger, A; Schindler, K; Schneider, B | 1 |
| Abeli, C; Adorni, F; Bini, T; Bongiovanni, M; Castelnuovo, B; Chiesa, E; d'Arminio Monforte, A; Melzi, S; Sollima, S; Testa, L | 1 |
| Kerr, B; Kobayashi, T; Lankford, A; Maeda, Y; Patick, AK; Shetty, B; Webber, S; Wu, E; Zhang, KE; Zorbas, M | 1 |
| Baede-van Dijk, PA; Burger, DM; Hekster, YA; Hugen, PW; Koopmans, PP; Verweij-van Wissen, CP | 1 |
| Eron, JJ; Gillotin, C; Haubrich, R; Lang, W; Lou, Y; Sadler, BM; Stein, DS | 1 |
8 trial(s) available for nelfinavir and AIDS Seroconversion
| Article | Year |
|---|---|
Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Nelfinavir; Prospective Studies; RNA, Viral; Viral Load; Zidovudine | 2003 |
Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
Topics: Adult; Aged; Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Seropositivity; Humans; Lamivudine; Lymphocyte Activation; Male; Middle Aged; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; T-Lymphocyte Subsets; Zidovudine | 2004 |
Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Biotransformation; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Hepatitis C; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; Humans; Liver Cirrhosis; Male; Middle Aged; Nelfinavir; Quality Control; Spectrophotometry, Ultraviolet | 2005 |
Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons.
Topics: Adult; Drug Resistance; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Nevirapine; Polypharmacy; Prognosis; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir | 1999 |
Positive impact of protease inhibitors on body composition and energy expenditure in HIV-infected and AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Body Composition; Body Weight; Diet; Drug Therapy, Combination; Energy Intake; Energy Metabolism; Follow-Up Studies; HIV Protease Inhibitors; HIV Seropositivity; Humans; Nelfinavir; Weight Gain | 2000 |
Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Protease Inhibitors; HIV Seropositivity; Humans; Male; Nelfinavir; Ritonavir; RNA, Viral; Saquinavir; Time Factors; Treatment Failure; Treatment Outcome | 2000 |
Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aryl Hydrocarbon Hydroxylases; Body Weight; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Databases, Factual; Diarrhea; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Induction; Enzyme Inhibitors; Female; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; Humans; Male; Middle Aged; Mixed Function Oxygenases; Nelfinavir; Omeprazole | 2001 |
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
Topics: Adult; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Male; Mixed Function Oxygenases; Nelfinavir; Orosomucoid; Saquinavir; Sulfonamides | 2001 |
14 other study(ies) available for nelfinavir and AIDS Seroconversion
| Article | Year |
|---|---|
Marked tumor response and fatal hemoptysis during radiation for lung cancer in a human immunodeficiency virus-positive patient taking nelfinavir.
Topics: Carcinoma, Squamous Cell; Fatal Outcome; Hemoptysis; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Lung Neoplasms; Male; Nelfinavir | 2009 |
Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.
Topics: Adult; Drug Resistance; Female; Genes, Viral; Genotype; HIV; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV Seropositivity; Humans; Male; Middle Aged; Mutation; Nelfinavir | 2002 |
Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; HIV Protease Inhibitors; HIV Seropositivity; Humans; Male; Nelfinavir; T-Lymphocytes | 2003 |
Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo.
Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cohort Studies; Genetic Variation; Genotype; Haplotypes; HIV Protease Inhibitors; HIV Seropositivity; Humans; Leukocytes, Mononuclear; Mitochondrial Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Nelfinavir; Neoplasm Proteins; Pharmacogenetics; Phenotype; Polymorphism, Genetic; Ribosomal Proteins; Saccharomyces cerevisiae Proteins | 2005 |
Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.
Topics: Anticonvulsants; Antiretroviral Therapy, Highly Active; Blood Cell Count; Carbamazepine; Drug Interactions; Drug Therapy, Combination; HIV Protease Inhibitors; HIV Seropositivity; Humans; Liver Function Tests; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; Sleep Stages; Viral Load | 2006 |
[Adherence, pharmacokinetic "tolerance capacity" and HIV resistance development].
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Diagnosis, Differential; DNA Mutational Analysis; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Nelfinavir; Treatment Refusal; Viral Load; Zidovudine | 2006 |
A comparison of different protease inhibitors on coronary heart disease risk.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Coronary Disease; HIV Protease Inhibitors; HIV Seropositivity; Humans; Hyperlipidemias; Nelfinavir; Oligopeptides; Pyridines; Risk Factors | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cholesterol; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Multivariate Analysis; Nelfinavir; Nevirapine; Organophosphonates; Ritonavir; Stavudine; Tenofovir; Triglycerides; United States; White People | 2007 |
Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series.
Topics: Adolescent; Adult; Aged; Databases, Factual; Female; Hemophilia A; Hemorrhage; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Saquinavir; Treatment Outcome; United States; United States Food and Drug Administration; Zidovudine | 1999 |
Predictors of optimal virological response to potent antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; HIV Protease Inhibitors; HIV Seropositivity; Humans; Lamivudine; Male; Nelfinavir; Outcome Assessment, Health Care; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Viral Load; Zidovudine | 1999 |
Influence of protease inhibitor therapy on lipoprotein metabolism.
Topics: Adult; CD4 Lymphocyte Count; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Lipoproteins; Male; Middle Aged; Nelfinavir; Prospective Studies; Ritonavir; Viral Load | 1999 |
Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.
Topics: Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Didanosine; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Jurkat Cells; Nelfinavir; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; T-Lymphocytes; Viral Load; Zidovudine | 2000 |
Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Cohort Studies; Confidence Intervals; Drug Monitoring; Female; Follow-Up Studies; HIV Protease Inhibitors; HIV Seropositivity; Humans; Incidence; Indinavir; Italy; Male; Middle Aged; Multivariate Analysis; Nelfinavir; Prospective Studies; Risk Factors; Ritonavir; Saquinavir | 2000 |
Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.
Topics: Blood Proteins; Cell Line; Chromatography, Liquid; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Kinetics; Male; Mass Spectrometry; Microbial Sensitivity Tests; Nelfinavir | 2001 |